Oncostatin m receptor antigen binding proteins

Patent metadata

Field	Value
Publication number	US-2016137739-A1
Application number	US-201414891491-A
Country	US
Kind code	A1
Filing date	May 30, 2014
Priority date	May 30, 2013
Publication date	May 19, 2016
Grant date	—

Abstract

The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.

First claim

1 . An oncostatin M receptor (OSMR) antigen binding protein comprising:
a) a light chain variable domain having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29; b) a heavy chain variable domain having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11; or c) a light chain variable domain of a) and a heavy chain variable domain of b).

2 - 3 . (canceled)

4 . An oncostatin M receptor (OSMR) antigen binding protein, comprising:
a) a light chain variable domain having no more than ten amino acid additions, deletions or substitutions from the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29; b) a heavy chain variable domain having no more than ten amino acid additions, deletions or substitutions from the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO: 10, or SEQ ID NO:11; or c) the light chain variable domain of a) and the heavy chain variable domain of b).

5 - 6 . (canceled)

7 . The OSMR antigen binding protein of claim 1 , wherein the light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29.

8 . The OSMR antigen binding protein of claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11.

9 . An oncostatin M receptor (OSMR) antigen binding protein comprising:
a light chain variable domain comprising:
a) an LCDR1 having no more than three amino acid additions, deletions, or substitutions from the LCDR1 sequence set forth in SEQ ID NO:30; an LCDR2 having no more than three amino acid additions, deletions, or substitutions from the LCDR2 sequence set forth in SEQ ID NO:33; and an LCDR3 having no more than three amino acid additions, deletions, or substitutions from the LCDR3 sequence set forth in SEQ ID NO:36;
b) an LCDR1 having no more than three amino acid additions, deletions, or substitutions from the LCDR1 sequence set forth in SEQ ID NO:31; an LCDR2 having no more than three amino acid additions, deletions, or substitutions from the LCDR2 sequence set forth in SEQ ID NO:34; and an LCDR3 having no more than three amino acid additions, deletions, or substitutions from the LCDR3 sequence set forth in SEQ ID NO:37; or
c) an LCDR1 having no more than three amino acid additions, deletions, or substitutions from the LCDR1 sequence set forth in SEQ ID NO:32; an LCDR2 having no more than three amino acid additions, deletions, or substitutions from the LCDR2 sequence set forth in SEQ ID NO:35; and an LCDR3 having no more than three amino acid additions, deletions, or substitutions from the LCDR3 sequence set forth in SEQ ID NO:38; and
a heavy chain variable domain comprising:
d) an HCDR1 having no more than three amino acid additions, deletions, or substitutions from the HCDR1 sequence set forth in SEQ ID NO: 12; an HCDR2 having no more than three amino acid additions, deletions, or substitutions from the HCDR2 sequence set forth in SEQ ID NO: 15; and an HCDR3 having no more than three amino acid additions, deletions, or substitutions from the HCDR3 sequence set forth in SEQ ID NO: 18;
e) an HCDR1 having no more than three amino acid additions, deletions, or substitutions from the HCDR1 sequence set forth in SEQ ID NO: 13; an HCDR2 having no more than three amino acid additions, deletions, or substitutions from the HCDR2 sequence set forth in SEQ ID NO: 16; and an HCDR3 having no more than three amino acid additions, deletions, or substitutions from the HCDR3 sequence set forth in SEQ ID NO: 19; or
f) an HCDR1 having no more than three amino acid additions, deletions, or substitutions from the HCDR1 sequence set forth in SEQ ID NO: 14; an HCDR2 having no more than three amino acid additions, deletions, or substitutions from the HCDR2 sequence set forth in SEQ ID NO: 17; and an HCDR3 having no more than three amino acid additions, deletions, or substitutions from the HCDR3 sequence set forth in SEQ ID NO:20.

10 . (canceled)

11 . The OSMR antigen binding protein of claim 9 , wherein the light chain variable domain comprises an LCDR1 as set forth in SEQ ID NO:30; an LCDR2 sequence as set forth in SEQ ID NO:33; and an LCDR3 sequence as set forth in SEQ ID NO:36; and the heavy chain variable domain comprises an HCDR1 as set forth in SEQ ID NO: 12; an HCDR2 sequence as set forth in SEQ ID NO: 15; and an HCDR3 sequence as set forth in SEQ ID NO:18.

12 . (canceled)

13 . The OSMR antigen binding protein of claim 9 , wherein the light chain variable domain comprises an LCDR1 as set forth in SEQ ID NO:31; an LCDR2 sequence as set forth in SEQ ID NO:34; and an LCDR3 sequence as set forth in SEQ ID NO:37; and the heavy chain variable domain comprises an HCDR1 as set forth in SEQ ID NO: 13; an HCDR2 sequence as set forth in SEQ ID NO: 16; and an HCDR3 sequence as set forth in SEQ ID NO:19.

14 . (canceled)

15 . The OSMR antigen binding protein of claim 9 , wherein the light chain variable domain comprises an LCDR1 as set forth in SEQ ID NO:32; an LCDR2 sequence as set forth in SEQ ID NO:35; and an LCDR3 sequence as set forth in SEQ ID NO:38; and the heavy chain variable domain comprises an HCDR1 as set forth in SEQ ID NO: 14; an HCDR2 sequence as set forth in SEQ ID NO: 17; and an HCDR3 sequence as set forth in SEQ ID NO:20.

16 - 24 . (canceled)

25 . The OSMR antigen binding protein of claim 1 , wherein the antigen binding protein is an antibody.

26 . The OSMR antigen binding protein of claim 25 , wherein the antibody is a human antibody.

27 . The OSMR antigen binding protein of claim 26 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:24 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:6.

28 . The OSMR antigen binding protein of claim 26 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:25 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:7.

29 . The OSMR antigen binding protein of claim 26 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:26 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:8.

30 . The OSMR antigen binding protein of claim 25 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:24 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:50.

31 . The OSMR antigen binding protein of claim 25 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:25 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:51.

32 . The OSMR antigen binding protein of claim 25 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:26 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:52.

33 . An isolated nucleic acid encoding a polypeptide, said polypeptide comprising:
a) a light chain variable domain having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29; b) a heavy chain variable domain having at least 95% identity to the amino acid sequence set

Assignees

• Biogen Ma Inc

Inventors

• Arnett Heather A
• Escobar Sabine S
• King Chadwick T
• Lim Ai Ching
• Narayanan Saravanakumar
• Weinreb Paul H
• Pederson Nels E

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title